DALLAS--(BUSINESS WIRE)--Gore Range Capital is pleased to announce that Evommune, Inc., a private R&D company and innovation engine in the area of chronic inflammation, won the third edition of the Gore Range Capital Skin Health Innovation Competition held at the Fall Clinical Dermatology Conference in Las Vegas.
Evommune is using the skin as the lens to uncover novel approaches for accelerating the development of vital medicines across immunology and dermatology. Evommune co-founders are President and CEO, Luis Pena, Chief Medical Officer, Eugene A. Bauer, M.D., former Dean of Stanford's School of Medicine, and Senior Vice President of Research, Hans Hofland, PhD.
“We are excited to win the Gore Range Capital Skin Health Innovation Competition,” Dr. Bauer said. “Our goal is to continue to develop medicines that simplify the lives of patients, and we appreciate every opportunity to present our findings to pre-eminent clinicians and industry thought leaders.”
Evommune recently raised $83 million in Series A financing to continue research and development of transformative therapies to treat patients with immune-mediated and chronic inflammatory diseases. The company has four investigational compounds in the pipeline; three have been in-licensed via an exclusive agreement with Dermira, a wholly-owned subsidiary of Eli Lilly and Company.
The other finalists were Citius Pharmaceuticals, Inc. and Sirnaomics. The winner was determined using a voting structure weighing both panel judges and people’s choice. Evommune joins the prestigious list of former winners: Eirion Therapeutics and NovaScan, Inc.
The competition is an annual event hosted during the Fall Clinical Dermatology Conference and sponsored by Gore Range Capital and DermX Media. This year’s event was the first to be held in-person.
DermX Media is a private medical education business focused on clinical dermatology. The company hosts five conferences a year and provides online and virtual content that reaches more than 20,000 skin health professionals (dermatologists, physician assistants, and nurse practitioners), in the United States. The Fall Clinical was held both in-person and virtually. Over 2,500 providers and industry members attended the conference.
Derek Maetzold, President and CEO of Castle Biosciences, was the keynote speaker for the competition. The guest judges for the competition included skin health experts and prominent clinicians - Dr. April Armstrong, Associate Dean of Keck School of Medicine USC; Dr. Valerie Callender, Medical Director and Founder of Callender Dermatology and Cosmetic Center; Miles Harrison, President & CEO of Novaestiq; Fauad Hasan, Chairman & CEO of Ornovi; Dr. Sandra Lee, aka Dr. Pimple Popper; and Dr. Mark Nestor, Director, Center for Clinical and Cosmetic Research and the Center for Cosmetic Enhancement.
“We are astonished at the caliber of companies that have presented at this competition since its inception,” says Ethan Rigel, Founder and Managing Partner of Gore Range Capital. “This is a testament to the level of innovation happening in the skin health space and we are glad that we have the unique privilege of getting a first look at the majority of the best opportunities within this space.”
About Gore Range Capital
Gore Range Capital is a venture capital firm investing in early-stage healthcare businesses with a focus on skin health. The firm blends the hands-on approach of operationally focused private equity with the early-stage guidance needed in venture capital. Gore Range offers not just capital, but operational, clinical, and scientific expertise that leverages the team’s deep industry relationships and its renowned industry advisory board. For more information, visit: https://www.gorerangecapital.com/
